Marea Therapeutics Provides Update on Corporate Progress Including Positive Topline Results from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease and Disclosure of Second Lead Pipeline Program for the Treatment of Acromegaly

Positive topline results from Phase 2a study of MAR001 demonstrate clinically meaningful reductions in remnant cholesterol and triglycerides; Phase 2b study expected to initiate in First Half 2025Second Lead Program announced, MAR002, a growth hormone receptor (GHR) antagonist for the treatment of acromegaly; Phase 1 study expected to initiate in Second Half 2025Marea to present at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15San Francisco, Calif. – January 9, 2025 – Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardio-endocrine diseases, today provided an update on the company’s recent progress and upcoming milestones for 2025 in advance of the J.P. Morgan 43rd Annual Healthcare Conference, taking place from January 13-16, 2025 in San Francisco, CA.“Since our launch in June 2024, Marea has made excellent progress across a number of areas,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. “Based on positive results from our Phase 2a study that demonstrate clinically meaningful reductions in remnant cholesterol and triglycerides, we are preparing to advance MAR001 into Phase 2b clinical development in the first half of 2025. These data demonstrate the potential of MAR001 to address the untreated lipid and metabolic drivers of cardiovascular disease in high-risk patients. In addition, we announced our second lead pipeline program for the treatment of acromegaly with clinical development expected to initiate in the second half of 2025. Our strong pipeline progress, further fueled by the recent expansion of our management team and board of directors, positions us for an important 2025 as we seek to accelerate a new generation of medicines for cardiometabolic and endocrine diseases.” Positive Phase 2a Topline Results for MAR001 MAR001 is a potential first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. The primary objective of Marea’s randomized, double-blind, placebo-controlled Phase 2a clinical trial was to characterize the safety and tolerability of multiple doses of MAR001 in participants with metabolic dysfunction. Secondary objectives were to describe the serum concentration of MAR001 at selected timepoints and to characterize the effect of MAR001 on triglyceride and remnant cholesterol metabolism following 12 weeks of treatment. The study enrolled 55 participants with hypertriglyceridemia (fasting TGs ≥150 and ≤499 mg/dL) randomized to MAR001 or placebo (blinded, 2:1 MAR001:Placebo). Ten participants were randomized to the 150 mg MAR001 arm, 17 participants to the 450 mg MAR001 arm, 9 participants to the 300 mg arm, and 19 participants to placebo. Topline results showed meaningful reductions in remnant cholesterol and triglycerides. MAR001 at 300mg and 450mg demonstrated approximately 50% placebo-corrected remnant cholesterol lowering in the target population, predicting meaningful clinical benefit. MAR001 was generally well tolerated. There have been no deaths or serious adverse events in any arm, and no adverse events leading to study drug discontinuation. The company plans on presenting a fuller data set at an upcoming medical meeting. Marea expects to initiate a Phase 2b clinical trial with MAR001 in the first half of 2025. “These clinical data, coupled with the remarkable human genetic validation of ANGPTL4, the target for MAR001, establishes MAR001 as one of the most promising candidates advancing into late-stage development for treating residual cardiovascular risk in the patients who remain at highest risk despite aggressive standard of care therapies,” said Ethan Weiss, M.D., chief scientific officer of Marea. Second Lead Pipeline Program Announced: MAR002 for the Treatment of Acromegaly MAR002 is a potential first-in-class anti-growth hormone receptor (GHR) antibody being developed for acromegaly. Acromegaly is a life-shortening disease where much of the morbidity is caused by insulin resistance, lipotoxicity, and cardiovascular events. Current therapies for acromegaly are associated with suboptimal disease control. It is estimated there are more than 30,000 patients with acromegaly in the U.S. Marea expects to initiate a Phase 1 clinical trial with MAR002 in the second half of 2025. Other Corporate Highlights In June 2024, Marea announced $190 million in combined Series A and B financings. Continued to build out senior leadership team; announced the appointments of Ian Clements, Ph.D., as chief financial officer, Rebecca Juliano, Ph.D., as chief development officer, and Max Zeiberg as senior vice president, corporate development. Added Robert A. Harrington, M.D., to Board of Directors. Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Management will participate in the 43rd Annual J.P Morgan Healthcare Conference. In addition to hosting meetings, management will present an overview of the Company on Wednesday, January 15, at 11:30 a.m. PT in San Francisco. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardio-endocrine diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X. Media Contact: Katie Engleman, [email protected] About Careers Home News Pipeline Privacy Policy Science Terms and Conditions {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/mareatx/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} var __VUE_WORDPRESS__ = {"routing":{"category_base":"","page_on_front":"home","page_for_posts":null,"permalink_structure":"/%category%/%postname%/","show_on_front":"page","tag_base":"","url":"https://www.mareatx.com","page_type":"post","root":"https://www.mareatx.com/wp-json/","base_url":"https://www.mareatx.com","base_path":"/","site_name":"Marea Therapeutics","components":["Page","SingleTeam","SinglePost","404Page"],"routes":[{"name":"Page-about","path":"/about/","component":"Page","props":{"default":true,"post_type":"page","isHomepage":false,"slug":"about"},"meta":{"frontpage":false,"bodyClass":"","title":"About","slug":"about","logo_color":"grey","header_color":"ocean"}},{"name":"Page-careers","path":"/careers/","component":"Page","props":{"default":true,"post_type":"page","isHomepage":false,"slug":"careers"},"meta":{"frontpage":false,"bodyClass":"","title":"Careers","slug":"careers","logo_color":"blue","header_color":"ocean"}},{"name":"Frontpage","path":"/","component":"Page","params":{"post_slug":"home"},"props":{"default":true,"slug":"home","post_type":"page","isHomepage":true},"meta":{"frontpage":true,"bodyClass":"home","title":"Home","slug":"home","logo_color":"blue","header_color":"ocean"}},{"name":"Page-news","path":"/news/","component":"Page","props":{"default":true,"post_type":"page","isHomepage":false,"slug":"news"},"meta":{"frontpage":false,"bodyClass":"","title":"News","slug":"news","logo_color":"blue","header_color":"ocean"}},{"name":"Page-pipeline","path":"/pipeline/","component":"Page","props":{"default":true,"post_type":"page","isHomepage":false,"slug":"pipeline"},"meta":{"frontpage":false,"bodyClass":"","title":"Pipeline","slug":"pipeline","logo_color":"green","header_color":"ocean"}},{"name":"Page-privacy-policy","path":"/privacy-policy/","component":"Page","props":{"default":true,"post_type":"page","isHomepage":false,"slug":"privacy-policy"},"meta":{"frontpage":false,"bodyClass":"","title":"Privacy Policy","slug":"privacy-policy","logo_color":"blue","header_color":"ocean"}},{"name":"Page-science","path":"/science/","component":"Page","props":{"default":true,"post_type":"page","isHomepage":false,"slug":"science"},"meta":{"frontpage":false,"bodyClass":"","title":"Science","slug":"science","logo_color":"grey","header_color":"yellow"}},{"name":"Page-terms-and-conditions","path":"/terms-and-conditions/","component":"Page","props":{"default":true,"post_type":"page","isHomepage":false,"slug":"terms-and-conditions"},"meta":{"frontpage":false,"bodyClass":"","title":"Terms and Conditions","slug":"terms-and-conditions","logo_color":"blue","header_color":"ocean"}},{"name":"Team-shishir-gadam-ph-d","path":"/team/shishir-gadam-ph-d/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"shishir-gadam-ph-d"},"meta":{"frontpage":false,"bodyClass":"","title":"Shishir Gadam, Ph.D.","slug":"shishir-gadam-ph-d","logo_color":"blue","header_color":null}},{"name":"Team-charmi-turner","path":"/team/charmi-turner/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"charmi-turner"},"meta":{"frontpage":false,"bodyClass":"","title":"Charmi Turner","slug":"charmi-turner","logo_color":"blue","header_color":null}},{"name":"Team-scott-wasserman-m-d","path":"/team/scott-wasserman-m-d/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"scott-wasserman-m-d"},"meta":{"frontpage":false,"bodyClass":"","title":"Scott Wasserman, M.D.","slug":"scott-wasserman-m-d","logo_color":"blue","header_color":null}},{"name":"Team-daniel-rader-m-d","path":"/team/daniel-rader-m-d/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"daniel-rader-m-d"},"meta":{"frontpage":false,"bodyClass":"","title":"Daniel Rader, M.D.","slug":"daniel-rader-m-d","logo_color":"blue","header_color":null}},{"name":"Team-joshua-rabinowitz-m-d-ph-d","path":"/team/joshua-rabinowitz-m-d-ph-d/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"joshua-rabinowitz-m-d-ph-d"},"meta":{"frontpage":false,"bodyClass":"","title":"Joshua Rabinowitz, M.D., Ph.D.","slug":"joshua-rabinowitz-m-d-ph-d","logo_color":"blue","header_color":null}},{"name":"Team-sir-stephen-orahilly-m-d-frs","path":"/team/sir-stephen-orahilly-m-d-frs/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"sir-stephen-orahilly-m-d-frs"},"meta":{"frontpage":false,"bodyClass":"","title":"Sir Stephen O\u2019Rahilly, M.D., FRS","slug":"sir-stephen-orahilly-m-d-frs","logo_color":"blue","header_color":null}},{"name":"Team-charles-homcy-m-d","path":"/team/charles-homcy-m-d/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"charles-homcy-m-d"},"meta":{"frontpage":false,"bodyClass":"","title":"Charles Homcy, M.D.","slug":"charles-homcy-m-d","logo_color":"blue","header_color":null}},{"name":"Team-priscilla-hsue-m-d","path":"/team/priscilla-hsue-m-d/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"priscilla-hsue-m-d"},"meta":{"frontpage":false,"bodyClass":"","title":"Priscilla Hsue, M.D.","slug":"priscilla-hsue-m-d","logo_color":"blue","header_color":null}},{"name":"Team-morris-j-birnbaum-m-d","path":"/team/morris-j-birnbaum-m-d/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"morris-j-birnbaum-m-d"},"meta":{"frontpage":false,"bodyClass":"","title":"Morris J. Birnbaum, M.D.","slug":"morris-j-birnbaum-m-d","logo_color":"blue","header_color":null}},{"name":"Team-robert-harrington","path":"/team/robert-harrington/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"robert-harrington"},"meta":{"frontpage":false,"bodyClass":"","title":"Robert A. Harrington, M.D.","slug":"robert-harrington","logo_color":"blue","header_color":null}},{"name":"Team-max-zeiberg","path":"/team/max-zeiberg/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"max-zeiberg"},"meta":{"frontpage":false,"bodyClass":"","title":"Max Zeiberg, MBA","slug":"max-zeiberg","logo_color":"blue","header_color":null}},{"name":"Team-rebecca-juliano","path":"/team/rebecca-juliano/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"rebecca-juliano"},"meta":{"frontpage":false,"bodyClass":"","title":"Rebecca Juliano, Ph.D.","slug":"rebecca-juliano","logo_color":"blue","header_color":null}},{"name":"Team-jeffrey-tong","path":"/team/jeffrey-tong/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"jeffrey-tong"},"meta":{"frontpage":false,"bodyClass":"","title":"Jeffrey Tong, Ph.D.","slug":"jeffrey-tong","logo_color":"blue","header_color":null}},{"name":"Team-aaron-royston","path":"/team/aaron-royston/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"aaron-royston"},"meta":{"frontpage":false,"bodyClass":"","title":"Aaron Royston, M.D.","slug":"aaron-royston","logo_color":"blue","header_color":null}},{"name":"Team-josh-lehrer","path":"/team/josh-lehrer/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"josh-lehrer"},"meta":{"frontpage":false,"bodyClass":"","title":"Josh Lehrer, M.D., M.Phil., FACC","slug":"josh-lehrer","logo_color":"blue","header_color":null}},{"name":"Team-maha-katabi","path":"/team/maha-katabi/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"maha-katabi"},"meta":{"frontpage":false,"bodyClass":"","title":"Maha Katabi, Ph.D.","slug":"maha-katabi","logo_color":"blue","header_color":null}},{"name":"Team-chris-garabedian","path":"/team/chris-garabedian/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"chris-garabedian"},"meta":{"frontpage":false,"bodyClass":"","title":"Chris Garabedian","slug":"chris-garabedian","logo_color":"blue","header_color":null}},{"name":"Team-vyas-ramanan","path":"/team/vyas-ramanan/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"vyas-ramanan"},"meta":{"frontpage":false,"bodyClass":"","title":"Vyas Ramanan, Ph.D.","slug":"vyas-ramanan","logo_color":"blue","header_color":null}},{"name":"Team-regina-salvat","path":"/team/regina-salvat/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"regina-salvat"},"meta":{"frontpage":false,"bodyClass":"","title":"Regina Salvat, Ph.D.","slug":"regina-salvat","logo_color":"blue","header_color":null}},{"name":"Team-ted-love","path":"/team/ted-love/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"ted-love"},"meta":{"frontpage":false,"bodyClass":"","title":"Ted Love, M.D.","slug":"ted-love","logo_color":"blue","header_color":null}},{"name":"Team-ethan-weiss","path":"/team/ethan-weiss/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"ethan-weiss"},"meta":{"frontpage":false,"bodyClass":"","title":"Ethan Weiss, M.D.","slug":"ethan-weiss","logo_color":"blue","header_color":null}},{"name":"Team-joshua-rabinowitz","path":"/team/joshua-rabinowitz/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"joshua-rabinowitz"},"meta":{"frontpage":false,"bodyClass":"","title":"Joshua Rabinowitz, M.D., Ph.D.","slug":"joshua-rabinowitz","logo_color":"blue","header_color":null}},{"name":"Team-stephen-orahilly","path":"/team/stephen-orahilly/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"stephen-orahilly"},"meta":{"frontpage":false,"bodyClass":"","title":"Sir Stephen O\u2019Rahilly, M.D., FRS","slug":"stephen-orahilly","logo_color":"blue","header_color":null}},{"name":"Team-charles-homcy","path":"/team/charles-homcy/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"charles-homcy"},"meta":{"frontpage":false,"bodyClass":"","title":"Charles Homcy, M.D.","slug":"charles-homcy","logo_color":"blue","header_color":null}},{"name":"Team-ethan-weiss-2","path":"/team/ethan-weiss-2/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"ethan-weiss-2"},"meta":{"frontpage":false,"bodyClass":"","title":"Ethan Weiss, M.D.","slug":"ethan-weiss-2","logo_color":"blue","header_color":null}},{"name":"Team-precillia-redmond","path":"/team/precillia-redmond/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"precillia-redmond"},"meta":{"frontpage":false,"bodyClass":"","title":"Precillia Redmond, MBA","slug":"precillia-redmond","logo_color":"blue","header_color":null}},{"name":"Team-caitlin-murray","path":"/team/caitlin-murray/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"caitlin-murray"},"meta":{"frontpage":false,"bodyClass":"","title":"Caitlin Murray, Esq.","slug":"caitlin-murray","logo_color":"blue","header_color":null}},{"name":"Team-josh-lehrer-2","path":"/team/josh-lehrer-2/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"josh-lehrer-2"},"meta":{"frontpage":false,"bodyClass":"","title":"Josh Lehrer, M.D., M.Phil., FACC","slug":"josh-lehrer-2","logo_color":"blue","header_color":null}},{"name":"Team-mark-joing","path":"/team/mark-joing/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"mark-joing"},"meta":{"frontpage":false,"bodyClass":"","title":"Mark Joing, MBA","slug":"mark-joing","logo_color":"blue","header_color":null}},{"name":"Team-ian-clements","path":"/team/ian-clements/","component":"SingleTeam","props":{"default":true,"post_type":"team","isHomepage":false,"slug":"ian-clements"},"meta":{"frontpage":false,"bodyClass":"","title":"Ian Clements, Ph.D.","slug":"ian-clements","logo_color":"blue","header_color":null}},{"name":"Post-marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-upcoming-late-breaking-presentation-of-mar001-clinical-data-at-the-american-heart-association-scientific-sessions-2026","path":"/press-releases/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-upcoming-late-breaking-presentation-of-mar001-clinical-data-at-the-american-heart-association-scientific-sessions-2026/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-upcoming-late-breaking-presentation-of-mar001-clinical-data-at-the-american-heart-association-scientific-sessions-2026"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026","logo_color":"blue","slug":"marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-upcoming-late-breaking-presentation-of-mar001-clinical-data-at-the-american-heart-association-scientific-sessions-2026"}},{"name":"Post-marea-corporate-presentation","path":"/presentations/marea-corporate-presentation/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-corporate-presentation"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Corporate Presentation","logo_color":"blue","slug":"marea-corporate-presentation"}},{"name":"Post-lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million-concurrent-private-placement","path":"/press-releases/lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million-concurrent-private-placement/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million-concurrent-private-placement"},"meta":{"frontpage":false,"bodyClass":"","title":"Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement","logo_color":"blue","slug":"lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million-concurrent-private-placement"}},{"name":"Post-san-francisco-business-times-best-places-to-work-2026","path":"/in-the-news/san-francisco-business-times-best-places-to-work-2026/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"san-francisco-business-times-best-places-to-work-2026"},"meta":{"frontpage":false,"bodyClass":"","title":"San Francisco Business Times Best Places to Work 2026","logo_color":"blue","slug":"san-francisco-business-times-best-places-to-work-2026"}},{"name":"Post-marea-therapeutics-presents-phase-1-data-supporting-potential-best-in-disease-profile-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026","path":"/press-releases/marea-therapeutics-presents-phase-1-data-supporting-potential-best-in-disease-profile-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-presents-phase-1-data-supporting-potential-best-in-disease-profile-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026","logo_color":"blue","slug":"marea-therapeutics-presents-phase-1-data-supporting-potential-best-in-disease-profile-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026"}},{"name":"Post-marea-therapeutics-to-present-data-from-phase-1-study-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026","path":"/press-releases/marea-therapeutics-to-present-data-from-phase-1-study-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-to-present-data-from-phase-1-study-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics to Present Data from Phase 1 Study of MAR002 for the Treatment of Acromegaly at ENDO 2026","logo_color":"blue","slug":"marea-therapeutics-to-present-data-from-phase-1-study-of-mar002-for-the-treatment-of-acromegaly-at-endo-2026"}},{"name":"Post-marea-therapeutics-unveils-positive-topline-phase-1-data-for-mar002-in-acromegaly-demonstrates-potential-for-best-in-disease-efficacy-and-dosing-profile","path":"/press-releases/marea-therapeutics-unveils-positive-topline-phase-1-data-for-mar002-in-acromegaly-demonstrates-potential-for-best-in-disease-efficacy-and-dosing-profile/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-unveils-positive-topline-phase-1-data-for-mar002-in-acromegaly-demonstrates-potential-for-best-in-disease-efficacy-and-dosing-profile"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile","logo_color":"blue","slug":"marea-therapeutics-unveils-positive-topline-phase-1-data-for-mar002-in-acromegaly-demonstrates-potential-for-best-in-disease-efficacy-and-dosing-profile"}},{"name":"Post-marea-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference","path":"/press-releases/marea-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference","logo_color":"blue","slug":"marea-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference"}},{"name":"Post-2025-global-cvct-forum-a-novel-angptl4-inhibitory-antibody-mar001-safey-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans","path":"/publications-posters/2025-global-cvct-forum-a-novel-angptl4-inhibitory-antibody-mar001-safey-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"2025-global-cvct-forum-a-novel-angptl4-inhibitory-antibody-mar001-safey-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans"},"meta":{"frontpage":false,"bodyClass":"","title":"2025 Global CVCT Forum: A Novel ANGPTL4 Inhibitory Antibody (MAR001) Safey Lowers Plasma Triglycerides and Remnant Cholesterol in Humans","logo_color":"blue","slug":"2025-global-cvct-forum-a-novel-angptl4-inhibitory-antibody-mar001-safey-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans"}},{"name":"Post-angptl4-inhibition-phase-2a-and-ongoing-trials","path":"/publications-posters/angptl4-inhibition-phase-2a-and-ongoing-trials/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"angptl4-inhibition-phase-2a-and-ongoing-trials"},"meta":{"frontpage":false,"bodyClass":"","title":"TG Forum: ANGPTL4 inhibition: Phase 2a and ongoing trials","logo_color":"blue","slug":"angptl4-inhibition-phase-2a-and-ongoing-trials"}},{"name":"Post-angptl4-new-insights-into-an-old-lipid-regulatory-protein","path":"/publications-posters/angptl4-new-insights-into-an-old-lipid-regulatory-protein/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"angptl4-new-insights-into-an-old-lipid-regulatory-protein"},"meta":{"frontpage":false,"bodyClass":"","title":"TG Forum: ANGPTL4: New insights into an \u201cold\u201d lipid regulatory protein","logo_color":"blue","slug":"angptl4-new-insights-into-an-old-lipid-regulatory-protein"}},{"name":"Post-marea-therapeutics-enrolls-first-participant-in-phase-1-clinical-study-evaluating-mar002-for-acromegaly","path":"/press-releases/marea-therapeutics-enrolls-first-participant-in-phase-1-clinical-study-evaluating-mar002-for-acromegaly/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-enrolls-first-participant-in-phase-1-clinical-study-evaluating-mar002-for-acromegaly"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly","logo_color":"blue","slug":"marea-therapeutics-enrolls-first-participant-in-phase-1-clinical-study-evaluating-mar002-for-acromegaly"}},{"name":"Post-marea-therapeutics-enrolls-first-patient-in-phase-2b-tydal-timi-78-clinical-study-evaluating-mar001-in-adults-at-risk-of-ascvd","path":"/press-releases/marea-therapeutics-enrolls-first-patient-in-phase-2b-tydal-timi-78-clinical-study-evaluating-mar001-in-adults-at-risk-of-ascvd/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-enrolls-first-patient-in-phase-2b-tydal-timi-78-clinical-study-evaluating-mar001-in-adults-at-risk-of-ascvd"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD","logo_color":"blue","slug":"marea-therapeutics-enrolls-first-patient-in-phase-2b-tydal-timi-78-clinical-study-evaluating-mar001-in-adults-at-risk-of-ascvd"}},{"name":"Post-marea-therapeutics-presents-preclinical-data-on-novel-growth-hormone-receptor-antagonist-antibody-mar002-for-the-treatment-of-acromegaly-at-endo-2025","path":"/press-releases/marea-therapeutics-presents-preclinical-data-on-novel-growth-hormone-receptor-antagonist-antibody-mar002-for-the-treatment-of-acromegaly-at-endo-2025/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-presents-preclinical-data-on-novel-growth-hormone-receptor-antagonist-antibody-mar002-for-the-treatment-of-acromegaly-at-endo-2025"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025","logo_color":"blue","slug":"marea-therapeutics-presents-preclinical-data-on-novel-growth-hormone-receptor-antagonist-antibody-mar002-for-the-treatment-of-acromegaly-at-endo-2025"}},{"name":"Post-marea-therapeutics-appoints-shishir-gadam-ph-d-as-chief-technical-officer","path":"/press-releases/marea-therapeutics-appoints-shishir-gadam-ph-d-as-chief-technical-officer/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-appoints-shishir-gadam-ph-d-as-chief-technical-officer"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer","logo_color":"blue","slug":"marea-therapeutics-appoints-shishir-gadam-ph-d-as-chief-technical-officer"}},{"name":"Post-marea-therapeutics-announces-oral-presentation-related-to-acromegaly-program-at-endo-2025","path":"/press-releases/marea-therapeutics-announces-oral-presentation-related-to-acromegaly-program-at-endo-2025/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-announces-oral-presentation-related-to-acromegaly-program-at-endo-2025"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025","logo_color":"blue","slug":"marea-therapeutics-announces-oral-presentation-related-to-acromegaly-program-at-endo-2025"}},{"name":"Post-marea-therapeutics-appoints-charmi-turner-as-senior-vice-president-people-culture","path":"/press-releases/marea-therapeutics-appoints-charmi-turner-as-senior-vice-president-people-culture/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-appoints-charmi-turner-as-senior-vice-president-people-culture"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture","logo_color":"blue","slug":"marea-therapeutics-appoints-charmi-turner-as-senior-vice-president-people-culture"}},{"name":"Post-marea-therapeutics-announces-publication-in-the-lancet-of-positive-data-from-phase-2a-clinical-trial-of-mar001-for-cardiovascular-disease","path":"/press-releases/marea-therapeutics-announces-publication-in-the-lancet-of-positive-data-from-phase-2a-clinical-trial-of-mar001-for-cardiovascular-disease/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-announces-publication-in-the-lancet-of-positive-data-from-phase-2a-clinical-trial-of-mar001-for-cardiovascular-disease"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease","logo_color":"blue","slug":"marea-therapeutics-announces-publication-in-the-lancet-of-positive-data-from-phase-2a-clinical-trial-of-mar001-for-cardiovascular-disease"}},{"name":"Post-the-lancet-safety-and-efficacy-of-a-novel-angptl4-inhibitory-antibody-for-lipid-lowering-results-from-phase-1-and-phase-1b-2a-clinical-studies","path":"/publications-posters/the-lancet-safety-and-efficacy-of-a-novel-angptl4-inhibitory-antibody-for-lipid-lowering-results-from-phase-1-and-phase-1b-2a-clinical-studies/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"the-lancet-safety-and-efficacy-of-a-novel-angptl4-inhibitory-antibody-for-lipid-lowering-results-from-phase-1-and-phase-1b-2a-clinical-studies"},"meta":{"frontpage":false,"bodyClass":"","title":"The Lancet: Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies","logo_color":"blue","slug":"the-lancet-safety-and-efficacy-of-a-novel-angptl4-inhibitory-antibody-for-lipid-lowering-results-from-phase-1-and-phase-1b-2a-clinical-studies"}},{"name":"Post-ebiomedicine-an-angptl4-inhibitory-antibody-safely-improves-lipid-profiles-in-non-human-primates","path":"/publications-posters/ebiomedicine-an-angptl4-inhibitory-antibody-safely-improves-lipid-profiles-in-non-human-primates/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"ebiomedicine-an-angptl4-inhibitory-antibody-safely-improves-lipid-profiles-in-non-human-primates"},"meta":{"frontpage":false,"bodyClass":"","title":"eBioMedicine: An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primates","logo_color":"blue","slug":"ebiomedicine-an-angptl4-inhibitory-antibody-safely-improves-lipid-profiles-in-non-human-primates"}},{"name":"Post-marea-named-as-one-of-the-best-places-to-work-in-the-bay-area-by-the-san-francisco-business-times-and-silicon-valley-business-journal-for-2025","path":"/in-the-news/marea-named-as-one-of-the-best-places-to-work-in-the-bay-area-by-the-san-francisco-business-times-and-silicon-valley-business-journal-for-2025/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-named-as-one-of-the-best-places-to-work-in-the-bay-area-by-the-san-francisco-business-times-and-silicon-valley-business-journal-for-2025"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea named as one of the Best Places to Work in the Bay Area by the San Francisco Business Times and Silicon Valley Business Journal for 2025","logo_color":"blue","slug":"marea-named-as-one-of-the-best-places-to-work-in-the-bay-area-by-the-san-francisco-business-times-and-silicon-valley-business-journal-for-2025"}},{"name":"Post-eas-2025-a-novel-angptl4-inhibitory-antibody-safely-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans","path":"/publications-posters/eas-2025-a-novel-angptl4-inhibitory-antibody-safely-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"eas-2025-a-novel-angptl4-inhibitory-antibody-safely-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans"},"meta":{"frontpage":false,"bodyClass":"","title":"EAS 2025: A Novel ANGPTL4 Inhibitory Antibody Safely Lowers Plasma Triglycerides and Remnant Cholesterol in Humans","logo_color":"blue","slug":"eas-2025-a-novel-angptl4-inhibitory-antibody-safely-lowers-plasma-triglycerides-and-remnant-cholesterol-in-humans"}},{"name":"Post-eas-2025-real-world-analysis-of-the-association-of-remnant-cholesterol-levels-with-major-cardiovascular-events-in-patients-with-atherosclerotic-cardiovascular-disease","path":"/publications-posters/eas-2025-real-world-analysis-of-the-association-of-remnant-cholesterol-levels-with-major-cardiovascular-events-in-patients-with-atherosclerotic-cardiovascular-disease/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"eas-2025-real-world-analysis-of-the-association-of-remnant-cholesterol-levels-with-major-cardiovascular-events-in-patients-with-atherosclerotic-cardiovascular-disease"},"meta":{"frontpage":false,"bodyClass":"","title":"EAS 2025: Real-world Analysis of the Association of Remnant Cholesterol Levels with Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease","logo_color":"blue","slug":"eas-2025-real-world-analysis-of-the-association-of-remnant-cholesterol-levels-with-major-cardiovascular-events-in-patients-with-atherosclerotic-cardiovascular-disease"}},{"name":"Post-stat-marea-drug-cuts-type-of-blood-fat-in-half-in-study","path":"/in-the-news/stat-marea-drug-cuts-type-of-blood-fat-in-half-in-study/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"stat-marea-drug-cuts-type-of-blood-fat-in-half-in-study"},"meta":{"frontpage":false,"bodyClass":"","title":"STAT: Marea drug cuts type of blood fat in half in study","logo_color":"blue","slug":"stat-marea-drug-cuts-type-of-blood-fat-in-half-in-study"}},{"name":"Post-sftb-marea-therapeutics-delivers-clinical-trial-win-for-drug-targeting-heart-attack-stroke","path":"/in-the-news/sftb-marea-therapeutics-delivers-clinical-trial-win-for-drug-targeting-heart-attack-stroke/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"sftb-marea-therapeutics-delivers-clinical-trial-win-for-drug-targeting-heart-attack-stroke"},"meta":{"frontpage":false,"bodyClass":"","title":"San Francisco Business Times: Marea Therapeutics delivers clinical trial win for drug targeting heart attack, stroke","logo_color":"blue","slug":"sftb-marea-therapeutics-delivers-clinical-trial-win-for-drug-targeting-heart-attack-stroke"}},{"name":"Post-marea-therapeutics-presents-positive-data-from-phase-2a-clinical-trial-of-mar001-being-developed-for-cardiovascular-disease-in-late-breaking-oral-session-at-the-93rd-eas-congress","path":"/press-releases/marea-therapeutics-presents-positive-data-from-phase-2a-clinical-trial-of-mar001-being-developed-for-cardiovascular-disease-in-late-breaking-oral-session-at-the-93rd-eas-congress/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-presents-positive-data-from-phase-2a-clinical-trial-of-mar001-being-developed-for-cardiovascular-disease-in-late-breaking-oral-session-at-the-93rd-eas-congress"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress","logo_color":"blue","slug":"marea-therapeutics-presents-positive-data-from-phase-2a-clinical-trial-of-mar001-being-developed-for-cardiovascular-disease-in-late-breaking-oral-session-at-the-93rd-eas-congress"}},{"name":"Post-marea-therapeutics-today-announced-acceptance-of-a-late-breaker-at-eascongress2025-for-its-angptl4-inhibitor-believed-to-be-the-first-ever-clinical-data-presented-for-this-lipid-lowering-target","path":"/in-the-news/marea-therapeutics-today-announced-acceptance-of-a-late-breaker-at-eascongress2025-for-its-angptl4-inhibitor-believed-to-be-the-first-ever-clinical-data-presented-for-this-lipid-lowering-target/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-today-announced-acceptance-of-a-late-breaker-at-eascongress2025-for-its-angptl4-inhibitor-believed-to-be-the-first-ever-clinical-data-presented-for-this-lipid-lowering-target"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target","logo_color":"blue","slug":"marea-therapeutics-today-announced-acceptance-of-a-late-breaker-at-eascongress2025-for-its-angptl4-inhibitor-believed-to-be-the-first-ever-clinical-data-presented-for-this-lipid-lowering-target"}},{"name":"Post-marea-therapeutics-announces-late-breaking-oral-presentation-at-the-93rd-eas-congress","path":"/press-releases/marea-therapeutics-announces-late-breaking-oral-presentation-at-the-93rd-eas-congress/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-announces-late-breaking-oral-presentation-at-the-93rd-eas-congress"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Announces Late-Breaking Oral Presentation at the 93rd\u00a0EAS Congress","logo_color":"blue","slug":"marea-therapeutics-announces-late-breaking-oral-presentation-at-the-93rd-eas-congress"}},{"name":"Post-marea-therapeutics-forms-clinical-scientific-advisory-board","path":"/press-releases/marea-therapeutics-forms-clinical-scientific-advisory-board/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-forms-clinical-scientific-advisory-board"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Forms Clinical Scientific Advisory Board\u00a0","logo_color":"blue","slug":"marea-therapeutics-forms-clinical-scientific-advisory-board"}},{"name":"Post-marea-therapeutics-provides-update-on-corporate-progress-including-positive-topline-results-from-phase-2a-clinical-trial-of-mar001","path":"/press-releases/marea-therapeutics-provides-update-on-corporate-progress-including-positive-topline-results-from-phase-2a-clinical-trial-of-mar001/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-provides-update-on-corporate-progress-including-positive-topline-results-from-phase-2a-clinical-trial-of-mar001"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Provides Update on Corporate Progress Including Positive Topline Results from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease and Disclosure of Second Lead Pipeline Program for the Treatment of Acromegaly","logo_color":"blue","slug":"marea-therapeutics-provides-update-on-corporate-progress-including-positive-topline-results-from-phase-2a-clinical-trial-of-mar001"}},{"name":"Post-marea-therapeutics-expands-management-team-and-board-of-directors","path":"/press-releases/marea-therapeutics-expands-management-team-and-board-of-directors/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-expands-management-team-and-board-of-directors"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Expands Management Team and Board of Directors","logo_color":"blue","slug":"marea-therapeutics-expands-management-team-and-board-of-directors"}},{"name":"Post-hello-world","path":"/in-the-news/hello-world/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"hello-world"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics launches with $190M, seeing a \u2018fixable problem\u2019 in a neglected cardiometabolic target","logo_color":"blue","slug":"hello-world"}},{"name":"Post-one-in-five-atherosclerotic-cardiovascular-disease-events-in-individuals-with-diabetes-attributed-to-elevated-remnant-cholesterol","path":"/publications-posters/one-in-five-atherosclerotic-cardiovascular-disease-events-in-individuals-with-diabetes-attributed-to-elevated-remnant-cholesterol/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"one-in-five-atherosclerotic-cardiovascular-disease-events-in-individuals-with-diabetes-attributed-to-elevated-remnant-cholesterol"},"meta":{"frontpage":false,"bodyClass":"","title":"One in Five Atherosclerotic Cardiovascular Disease Events in Individuals With Diabetes Attributed to Elevated Remnant Cholesterol","logo_color":"blue","slug":"one-in-five-atherosclerotic-cardiovascular-disease-events-in-individuals-with-diabetes-attributed-to-elevated-remnant-cholesterol"}},{"name":"Post-remnant-cholesterol-and-long-term-incidence-of-death-in-coronary-artery-disease-patients","path":"/publications-posters/remnant-cholesterol-and-long-term-incidence-of-death-in-coronary-artery-disease-patients/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"remnant-cholesterol-and-long-term-incidence-of-death-in-coronary-artery-disease-patients"},"meta":{"frontpage":false,"bodyClass":"","title":"Remnant cholesterol and long-term incidence of death in coronary artery disease patients","logo_color":"blue","slug":"remnant-cholesterol-and-long-term-incidence-of-death-in-coronary-artery-disease-patients"}},{"name":"Post-hello-world-2","path":"/press-releases/hello-world-2/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"hello-world-2"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Appoints Ian Clements as Chief Financial Officer","logo_color":"blue","slug":"hello-world-2"}},{"name":"Post-how-a-tweet-about-a-gene-discovered-long-ago-led-to-a-190-million-startup-and-maybe-hope-for-heart-disease","path":"/in-the-news/how-a-tweet-about-a-gene-discovered-long-ago-led-to-a-190-million-startup-and-maybe-hope-for-heart-disease/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"how-a-tweet-about-a-gene-discovered-long-ago-led-to-a-190-million-startup-and-maybe-hope-for-heart-disease"},"meta":{"frontpage":false,"bodyClass":"","title":"How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease","logo_color":"blue","slug":"how-a-tweet-about-a-gene-discovered-long-ago-led-to-a-190-million-startup-and-maybe-hope-for-heart-disease"}},{"name":"Post-marea-incubated-by-third-rock-gets-190m-to-take-aim-at-remnant-cholesterol","path":"/in-the-news/marea-incubated-by-third-rock-gets-190m-to-take-aim-at-remnant-cholesterol/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-incubated-by-third-rock-gets-190m-to-take-aim-at-remnant-cholesterol"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea, Incubated by Third Rock, gets $190M to take aim at Remnant Cholesterol","logo_color":"blue","slug":"marea-incubated-by-third-rock-gets-190m-to-take-aim-at-remnant-cholesterol"}},{"name":"Post-marea-therapeutics-launches-with-190m-seeing-a-fixable-problem-in-a-neglected-cardiometabolic-target","path":"/press-releases/marea-therapeutics-launches-with-190m-seeing-a-fixable-problem-in-a-neglected-cardiometabolic-target/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"marea-therapeutics-launches-with-190m-seeing-a-fixable-problem-in-a-neglected-cardiometabolic-target"},"meta":{"frontpage":false,"bodyClass":"","title":"Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases","logo_color":"blue","slug":"marea-therapeutics-launches-with-190m-seeing-a-fixable-problem-in-a-neglected-cardiometabolic-target"}},{"name":"Post-drug-target-mendelian-randomization-analysis-supports-lowering-plasma-angptl3-angptl4-and-apoc3-levels-as-strategies-for-reducing-cardiovascular-disease-risk-2","path":"/publications-posters/drug-target-mendelian-randomization-analysis-supports-lowering-plasma-angptl3-angptl4-and-apoc3-levels-as-strategies-for-reducing-cardiovascular-disease-risk-2/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"drug-target-mendelian-randomization-analysis-supports-lowering-plasma-angptl3-angptl4-and-apoc3-levels-as-strategies-for-reducing-cardiovascular-disease-risk-2"},"meta":{"frontpage":false,"bodyClass":"","title":"Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk\u00a0","logo_color":"blue","slug":"drug-target-mendelian-randomization-analysis-supports-lowering-plasma-angptl3-angptl4-and-apoc3-levels-as-strategies-for-reducing-cardiovascular-disease-risk-2"}},{"name":"Post-triglyceride-rich-lipoprotein-remnants-low-density-lipoproteins-and-risk-of-coronary-heart-disease-a-uk-biobank-study","path":"/publications-posters/triglyceride-rich-lipoprotein-remnants-low-density-lipoproteins-and-risk-of-coronary-heart-disease-a-uk-biobank-study/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"triglyceride-rich-lipoprotein-remnants-low-density-lipoproteins-and-risk-of-coronary-heart-disease-a-uk-biobank-study"},"meta":{"frontpage":false,"bodyClass":"","title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","logo_color":"blue","slug":"triglyceride-rich-lipoprotein-remnants-low-density-lipoproteins-and-risk-of-coronary-heart-disease-a-uk-biobank-study"}},{"name":"Post-triglyceride-rich-lipoprotein-remnants-low-density-lipoproteins-and-risk-of-coronary-heart-disease-a-uk-biobank-study-2","path":"/publications-posters/triglyceride-rich-lipoprotein-remnants-low-density-lipoproteins-and-risk-of-coronary-heart-disease-a-uk-biobank-study-2/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"triglyceride-rich-lipoprotein-remnants-low-density-lipoproteins-and-risk-of-coronary-heart-disease-a-uk-biobank-study-2"},"meta":{"frontpage":false,"bodyClass":"","title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","logo_color":"blue","slug":"triglyceride-rich-lipoprotein-remnants-low-density-lipoproteins-and-risk-of-coronary-heart-disease-a-uk-biobank-study-2"}},{"name":"Post-characterising-metabolomic-signatures-of-lipid-modifying-therapies-through-drug-target-mendelian-randomisation","path":"/publications-posters/characterising-metabolomic-signatures-of-lipid-modifying-therapies-through-drug-target-mendelian-randomisation/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"characterising-metabolomic-signatures-of-lipid-modifying-therapies-through-drug-target-mendelian-randomisation"},"meta":{"frontpage":false,"bodyClass":"","title":"Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation","logo_color":"blue","slug":"characterising-metabolomic-signatures-of-lipid-modifying-therapies-through-drug-target-mendelian-randomisation"}},{"name":"Post-metabolic-profiling-of-angiopoietin-like-protein-3-and-4-inhibition-a-drug-target-mendelian-randomization-analysis","path":"/publications-posters/metabolic-profiling-of-angiopoietin-like-protein-3-and-4-inhibition-a-drug-target-mendelian-randomization-analysis/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"metabolic-profiling-of-angiopoietin-like-protein-3-and-4-inhibition-a-drug-target-mendelian-randomization-analysis"},"meta":{"frontpage":false,"bodyClass":"","title":"Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis","logo_color":"blue","slug":"metabolic-profiling-of-angiopoietin-like-protein-3-and-4-inhibition-a-drug-target-mendelian-randomization-analysis"}},{"name":"Post-contribution-of-remnant-cholesterol-to-cardiovascular-risk","path":"/publications-posters/contribution-of-remnant-cholesterol-to-cardiovascular-risk/","component":"SinglePost","props":{"default":true,"post_type":"post","isHomepage":false,"slug":"contribution-of-remnant-cholesterol-to-cardiovascular-risk"},"meta":{"frontpage":false,"bodyClass":"","title":"Contribution of remnant cholesterol to cardiovascular risk","logo_color":"blue","slug":"contribution-of-remnant-cholesterol-to-cardiovascular-risk"}},{"name":"404","path":"/:pathmatch(.*)*","component":"404Page","meta":{"frontpage":false,"bodyClass":"","title":"Page not found","slug":"404","logo_color":"green","header_color":"ocean"},"props":{"isHomepage":false,"slug":"404"}}]},"state":{"media":{"requests":[]},"menus":[{"id":"dGVybTo4","name":"Main Menu","slug":"main-menu","menuItems":{"nodes":[{"id":"cG9zdDoyNw==","label":"About","uri":"/about/","parentId":null,"cssClasses":[],"target":null,"childItems":{"nodes":[]}},{"id":"cG9zdDoyNg==","label":"Science","uri":"/science/","parentId":null,"cssClasses":[],"target":null,"childItems":{"nodes":[]}},{"id":"cG9zdDoyNQ==","label":"Pipeline","uri":"/pipeline/","parentId":null,"cssClasses":[],"target":null,"childItems":{"nodes":[]}},{"id":"cG9zdDoyNA==","label":"Careers","uri":"/careers/","parentId":null,"cssClasses":[],"target":null,"childItems":{"nodes":[]}},{"id":"cG9zdDoyMw==","label":"News","uri":"/news/","parentId":null,"cssClasses":[],"target":null,"childItems":{"nodes":[]}}]}}],"pages":{"requests":[]},"first_impression":null,"site":{"description":"A website for Marea Therapeutics","docTitle":"","loading":false,"introShown":false,"logo":false,"name":"Marea Therapeutics","posts_per_page":"10","url":"https://www.mareatx.com"},"acf_options":{"footer_contact_information":"\u003Cp\u003E(415) 766-3610\u003C/p\u003E\n\u003Cp\u003E\u003Ca href=\"mailto:[email protected]\"\[email protected]\u003C/a\u003E\u003C/p\u003E\n\u003Cp\u003E131 Oyster Point Boulevard, Floor 4\u003Cbr /\u003E\nSouth San Francisco, CA 94080\u003C/p\u003E\n","footer_links":[{"link":{"title":"Privacy Policy","url":"https://www.mareatx.com/privacy-policy/","target":""}},{"link":{"title":"Terms and Conditions","url":"https://www.mareatx.com/terms-and-conditions/","target":""}},{"link":""}],"footer_recognition_image":{"ID":271,"id":271,"title":"SFR_BPTW_2025_optimized","filename":"SFR_BPTW_2025_optimized.png","filesize":73932,"url":"https://www.mareatx.com/wp-content/uploads/2025/06/SFR_BPTW_2025_optimized.png","link":"https://www.mareatx.com/sfr_bptw_2025_optimized/","alt":"","author":"3","description":"","caption":"","name":"sfr_bptw_2025_optimized","status":"inherit","uploaded_to":0,"date":"2025-06-11 00:51:16","modified":"2025-06-11 00:51:16","menu_order":0,"mime_type":"image/png","type":"image","subtype":"png","icon":"https://www.mareatx.com/wp-includes/images/media/default.png","width":2071,"height":970,"sizes":{"thumbnail":"https://www.mareatx.com/wp-content/uploads/2025/06/SFR_BPTW_2025_optimized-150x150.png","thumbnail-width":150,"thumbnail-height":150,"16:9":"https://www.mareatx.com/wp-content/uploads/2025/06/SFR_BPTW_2025_optimized-1280x720.png","16:9-width":1280,"16:9-height":720,"1:1":"https://www.mareatx.com/wp-content/uploads/2025/06/SFR_BPTW_2025_optimized-800x800.png","1:1-width":800,"1:1-height":800,"3:2":"https://www.mareatx.com/wp-content/uploads/2025/06/SFR_BPTW_2025_optimized-750x500.png","3:2-width":750,"3:2-height":500,"hero":"https://www.mareatx.com/wp-content/uploads/2025/06/SFR_BPTW_2025_optimized-1920x970.png","hero-width":1920,"hero-height":970,"thumb":"https://www.mareatx.com/wp-content/uploads/2025/06/SFR_BPTW_2025_optimized-300x300.png","thumb-width":150,"thumb-height":150}},"linkedin":"https://www.linkedin.com/company/marea-therapeutics/","pages":"","site_logo_footer":{"ID":13,"id":13,"title":"green_logo","filename":"green_logo.svg","filesize":3491,"url":"https://www.mareatx.com/wp-content/uploads/2024/12/green_logo.svg","link":"https://www.mareatx.com/green_logo/","alt":"Marea Green logo","author":"3","description":"","caption":"","name":"green_logo","status":"inherit","uploaded_to":0,"date":"2024-12-10 20:09:51","modified":"2024-12-10 20:09:59","menu_order":0,"mime_type":"image/svg+xml","type":"image","subtype":"svg+xml","icon":"https://www.mareatx.com/wp-includes/images/media/default.png","width":253,"height":41,"sizes":{"thumbnail":"https://www.mareatx.com/wp-content/uploads/2024/12/green_logo.svg","thumbnail-width":150,"thumbnail-height":24,"16:9":"https://www.mareatx.com/wp-content/uploads/2024/12/green_logo.svg","16:9-width":253,"16:9-height":41,"1:1":"https://www.mareatx.com/wp-content/uploads/2024/12/green_logo.svg","1:1-width":253,"1:1-height":41,"3:2":"https://www.mareatx.com/wp-content/uploads/2024/12/green_logo.svg","3:2-width":253,"3:2-height":41,"hero":"https://www.mareatx.com/wp-content/uploads/2024/12/green_logo.svg","hero-width":253,"hero-height":41,"thumb":"https://www.mareatx.com/wp-content/uploads/2024/12/green_logo.svg","thumb-width":150,"thumb-height":24}},"x":"https://x.com/Marea_tx"}}}; //# sourceURL=main.js-js-extra (function(){function c(){var b=a.contentDocument||(a.contentWindow&&a.contentWindow.document);if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'a44da2d6cb57f65f',t:'MTc5MTA0ODIyMQ=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();

The release as fetched from its publisher. mareatx.com ↗